The Pharma Data

NOVEMBER 5, 2020

The FDA accepted for priority review, with a target action date of February 28, 2021 , the supplemental Biologics License Application (sBLA) for Libtayo ® (cemiplimab) as monotherapy to treat patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) with ?50% Corporate and Business Development Update.

Sales 40

Sales Production Manufacturing Antibody 40

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017. Before that, Ms.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

MAY 4, 2021

Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business (4) in the first three quarters of 2020 , is now included within the Hospital therapeutic area for all periods presented. Hospital products, which grew 10% operationally to $2.3

Vaccination 40

Vaccination Vaccine Production Sales 40